Back to results
US 10,478,421 B1Granted
Sortilin binding compounds, formulations, and uses thereof
AssigneesUniversity of Florida, University of Rochester
InventorsRobert Pleasants Sparks, Wayne Charles Guida, Janet Lindsay DeHoff-Sparks
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds and formulations thereof that can be capable of binding to sortilin or an analogue thereof. Also provided herein are methods of administering the compounds and formulation provided herein to a subject in need thereof.
Claims12
A method comprising:
- administering an amount of a compound according to Formula 2A
- or a pharmaceutical formulation thereof and an amount of compound 541
- or a pharmaceutical formulation thereof to a subject.
A method of inhibiting binding of a sortilin ligand to sortilin in a subject, the method comprising:
- administering to the subject an effective amount of a compound according to Formula 2A or a pharmaceutical formulation thereof
- and an effective amount of compound 541 or a pharmaceutical formulation thereof
- wherein the sortilin ligand is selected from the group consisting of:
- PCSK9, apolipoprotein B100, phosphatidylinositides, anionic phospholipids, anionic phospholipids contained on VLDL, amyloid beta, amyloid precursor protein, neurotensin or analogues of neurotensin, lipoprotein lipase, apolipoprotein AV and apolipoprotein E.
1 more element
A pharmaceutical formulation comprising:
- an effective amount of a compound having a structure according to Formula 2A
- an effective amount of compound 541
- and
- a pharmaceutically acceptable carrier.
1 more element
Dependencies are inferred from the claim text.